ReviewPeerJ2026
From mechanism to therapeutics: targeting the mitogen-activated protein kinase 1 (MAPK1)/extracellular signal-regulated kinase 2 (ERK2) pathway in renal fibrosis.
Review in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal fibrosis represents a crucial pathological event in the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD), with currently limited therapeutic options. As a key regulator of cell proliferation and differentiation, the mitogen-activated protein kinase 1 (MAPK1)/extracellular signal-regulated kinase 2 (ERK2) signaling pathway plays a central role in the development of renal fibrosis. This review aims to comprehensively elucidate the regulatory network of the MAPK1/ERK2 pathway, summarize recent advances in targeted therapies against renal fibrosis, and provide directions for developing novel anti-fibrotic drugs. Special attention is given to bioactive compounds, including both chemically synthesized drugs and natural products. Through cextensive literature searches of databases including PubMed and Web of Science, this review discusses how the MAPK1/ERK2 pathway responds to upstream signals to promote myofibroblast activation, inflammation, and aberrant extracellular matrix (ECM) deposition
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.